DBV Technologies SA (DBVT.OQ)
16 Feb 2018
Wed, Feb 14 2018
* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT
BRIEF-DBV Technologies announces positive data from Phase IIb trial and long-term study of Viaskin Peanut
* ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT
* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)
* CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age
DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.
Oct 20 Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.
* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT
* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III EXTENSION STUDY OF VIASKIN PEANUT
- Biotech Forum Daily Digest For February 15th
- U.S. Biotech/Pharma Sector Daily Observations Letter: February 14, 2018, Featuring DBV Technologies
- Aimmune Therapeutics - Desensitize Yourself For A Good Bet!
- Aimmune Therapeutics: Upside Into Q1 Data And Beyond
- DBV Technologies S.A. (DBVT) Presents At Citi Global Healthcare Conference - Slideshow
- Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies